Showing 1511-1520 of 2656 results for "".
- Roche’s Actemra/RoActemra Cuts Need for Ventilator Use in COVID-19 Pneumoniahttps://modernod.com/news/roches-actemra-roactemra-cuts-need-for-ventilator-use-in-covid-19-pneumonia/2478299/Roche announced results from the EMPACTA study on Friday, showing that patients with COVID-19-associated pneumonia who had Actemra/RoActemra (tocilizumab) added to standard care were 44% less likely to progress to mechanical ventilation or death compared to placebo plus standard care, meeting the
- Lilly, Incyte’s Olumiant Cuts Recovery Time When Added to Veklury in Hospitalized COVID-19 Patientshttps://modernod.com/news/lilly-incytes-olumiant-cuts-recovery-time-when-added-to-veklury-in-hospitalized-covid-19-patients/2478281/Eli Lilly and Incyte reported Monday that the JAK1/JAK2 inhibitor Olumiant (baricitinib) in combination with Gilead Sciences’ Veklury (remdesivir) met the primary endpoint of the ACTT 2 study by significantly reducing the time to recovery compared to Veklury alone in hospitalized patients w
- FDA Expands Emergency Use for Gilead’s Veklury to All Hospitalized COVID-19 Patientshttps://modernod.com/news/fda-expands-emergency-use-for-gileads-veklury-to-all-hospitalized-covid-19-patients/2478218/The FDA has broadened the scope of an existing emergency-use authorization (EUA) for Gilead Sciences’ Veklury (remdesivir) to include treatment of all hospitalized adult and paediatric patients with suspected or laboratory-confirmed COVID-19, regardless of the severity of their disease. In
- Moderna’s COVID-19 Vaccine Candidate Shows Promise in Older Adultshttps://modernod.com/news/modernas-covid-19-vaccine-candidate-shows-promise-in-older-adults/2478211/Interim data from a phase 1 study presented by Moderna showed that its experimental vaccine mRNA-1273 was safe and generated an immune response in people over the age of 55. Results from cohorts of older adults aged 56 to 70 years, as well as elderly participants 71 years and older, were detailed
- Dosing Begins in Phase 1 Study of AstraZeneca’s Antibody Combination for COVID-19https://modernod.com/news/dosing-begins-in-phase-1-study-of-astrazenecas-antibody-combination-for-covid-19/2478204/AstraZeneca announced that the first subjects have been dosed in a phase 1 study of AZD7442, a combination of two monoclonal antibodies under development for the prevention and treatment of COVID-19. Mene Pangalos, executive vice president of biopharmaceuticals R&D, said “this combinati
- US Secures At Least 100 Million Doses of Moderna’s COVID-19 Vaccine for $1.5 Billionhttps://modernod.com/news/us-secures-at-least-100-million-doses-of-modernas-covid-19-vaccine-for-1-5-billion/2478151/Moderna on Tuesday said it reached an agreement with the US government to supply millions of doses of its coronavirus vaccine candidate mRNA-1273. The award of up to $1.525 billion is for the manufacturing and delivery of 100 million doses of the vaccine, including incentive payments for timely d
- Roche’s Actemra/RoActemra Fails in Severe COVID-19-Associated Pneumonia Studyhttps://modernod.com/news/roches-actemra-roactemra-fails-in-severe-covid-19-associated-pneumonia-study/2478097/Roche said that a phase 3 study investigating Actemra/RoActemra (tocilizumab) in hospitalized adults with severe COVID-19-associated pneumonia failed to meet its primary endpoint of improved clinical status. The company launched the COVACTA trial in March in order to investigate the anti-IL-6 rec
- Dosing Begins in Moderna’s Late-Stage Study of COVID-19 Vaccine Candidatehttps://modernod.com/news/dosing-begins-in-modernas-late-stage-study-of-covid-19-vaccine-candidate/2478085/Moderna announced that patient dosing started in the phase 3 COVE study of its mRNA-based vaccine candidate against the novel coronavirus, sending company shares up as much as 11.3% on Monday. The trial of mRNA-1273 is being conducted in collaboration with the US National Institute of Allergy and
- US to PayNearly $2 Billion for 100 Million Doses of Pfizer, BioNTech’s COVID-19 Vaccinehttps://modernod.com/news/us-to-paynearly-2-billion-for-100-million-doses-of-pfizer-biontechs-covid-19-vaccine/2478067/Pfizer and BioNTech announced that the US government agreed to pay $1.95 billion for an initial order of 100 million doses of BNT162, an mRNA-based COVID-19 vaccine candidate being jointly developed by the companies. Under the deal, the government can also acquire up to 500 million more doses.
- Study Points to Potential New Approach to Treating Glaucoma and Alzheimer’s Diseasehttps://modernod.com/news/study-points-to-potential-new-approach-to-treating-glaucoma-and-alzheimers-disease/2478060/Researchers at Vanderbilt University Medical Center (VUMC) have shown for the first time that when one optic nerve in the eye is damaged, as in glaucoma, the opposite optic nerve comes to the rescue by sharing its metabolic energy. In doing so, however, the undamaged optic nerve becomes vu